Skip to main content
Premium Trial:

Request an Annual Quote

Geron Gives Up on Stem Cells

Biotech company Geron, long known for its pioneering research on stem cells, has announced that it will no longer conduct such research, reports New Scientist's Andy Coghlan. Geron's stem cell program was the largest in the world, and currently runs trials to treat various disorders and diseases with stem cell therapies, including one to treat people with spinal injuries, Coghlan says. The company cited financial reasons for its decision, but added that its choice was not based on the viability of stem cells as therapeutic tools. "The company had to choose between stem cells and cancer, and saw cancer as the better bet," Coghlan says.

University of Wisconsin researcher James Thomson — who in 1998 published a paper on human embryonic stem cells research with funding from Geron — tells Forbes' Matthew Herper that the company's decision "reflects how genuinely difficult it is to build a business around embryonic stem cell-based transplantation therapies." In addition, spinal cord injuries are particularly tough to treat, he says. However, Thomson adds, Geron researchers "are to be commended for blazing a trail that others can follow in getting the first clinical trial approved by the FDA, as such approvals should be easier in the future." Thomson has long said that the value of stem cells lies in their potential to help researchers develop better therapies, but not necessarily as therapies themselves, Forbes adds.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.